Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kathryn Friedman Flack"'
Autor:
Kathryn Friedman Flack, Jeremy Katzen
Publikováno v:
Chest. 163:744-745
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::49410614beef5341f7b928618f2a699e
https://doi.org/10.1016/j.chest.2022.12.020
https://doi.org/10.1016/j.chest.2022.12.020
Autor:
Stuart J. Connolly, Martina Brueckmann, Jennifer M. Kolb, Prapti Chatterjee-Murphy, Paul A. Reilly, James Aisenberg, John Ilgenfritz, Jay Desai, Michael D. Ezekowitz, Kathryn Friedman Flack, Lars Wallentin
Publikováno v:
Digestive Diseases and Sciences. 63:1878-1889
Different oral anticoagulants may be associated with gastrointestinal bleeding (GIB) from different locations or mucosal lesions. We aimed to test this hypothesis. Two blinded gastroenterologists independently analyzed source documents from the rando
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b49af508f688b4280cd4533827d6468
https://doi.org/10.1007/s10620-018-5007-6
https://doi.org/10.1007/s10620-018-5007-6
Autor:
Stuart J. Connolly, Martina Brueckmann, Kathryn Friedman Flack, Lars Wallentin, Salim Yusuf, James Aisenberg, Michael D. Ezekowitz, Jay Desai, Prapti Chatterjee, Paul A. Reilly, John Ilgenfritz, Jennifer M. Kolb
Publikováno v:
Clinical Gastroenterology and Hepatology. 15:682-690
Background & Aims Gastrointestinal (GI) bleeding in patients receiving anticoagulation agents can be caused by occult malignancies. We investigated the proportions and features of major GI bleeding (MGIB) events related to occult GI cancers in patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37c0d648733a7f6bdf39b70c05f2adf3
https://doi.org/10.1016/j.cgh.2016.10.011
https://doi.org/10.1016/j.cgh.2016.10.011
Autor:
Kathryn Friedman Flack, Christian T. Ruff, Michele Mercuri, Eugene Braunwald, Youngsook Choi, Robert P. Giugliano, Elliott M. Antman, Prapti Chatterjee-Murphy, Francesco Nordio, Jeffrey I. Weitz, James Aisenberg
Publikováno v:
Circulation: Cardiovascular Quality and Outcomes. 11
Background: The ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis In Myocardial Infarction) compared higher-dose edoxaban regimen (HD-ER) and lower-dose edoxaban regimen with well-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac1360f3018153638de6d8494e29c354
https://doi.org/10.1161/circoutcomes.117.003998
https://doi.org/10.1161/circoutcomes.117.003998